<DOC>
	<DOCNO>NCT00402558</DOCNO>
	<brief_summary>The goal clinical research study determine safety effect give special kind immune cell call `` alloreactive natural killer ( NK ) cell '' high dose chemotherapy allogeneic hematopoeitic stem cell transplantation goal define maximum tolerate dose NK cell . The NK cell donate relative certain genetic type blood call HLA , almost match . The stem cell receive come separate HLA match ( HLA A , B , C , DR ) relative unrelated donor . The safety treatment also study .</brief_summary>
	<brief_title>Alloreactive NK Cells Allogeneic Stem Cell Transplantation Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>NK cell part immune system ( cell body fight disease ) . Sometimes , NK cell react fight leukemia cell mismatch body certain HLA tissue type protein . When NK cell react , cell call `` alloreactive NK cell . '' In study , researcher collect alloreactive NK cell blood relative whose HLA proteins match exactly . The NK cell separate blood use machine call CLINIMACs system . This machine use special kind cell magnetic bead separate NK cell . The drug interleukin-2 add NK cell , improve function . The interleukin-2 washed cell sample give . The CliniMACS System medical device use separate type blood cell blood remove body leukapheresis . These separated cell process use treatment stem cell transplant . If able take part study , receive high-dose chemotherapy 4 day . You receive fludarabine 30 minute daily intravenous ( IV -- needle vein ) infusion . You also receive busulfan 3 hour IV day . About 2 day later , give infusion alloreactive NK cell IV . Patients receive one 3 dose level . Some patient receive interleukin-2 daily 4 day enhance function NK cell . Five ( 5 ) day NK cell infusion , thymoglobulin give IV daily 3 day . Thymoglobulin immunosuppressive treatment reduce risk graft rejection . Then blood stem cell administer IV different stem cell donor whose HLA type match . You receive drug tacrolimus methotrexate help low risk reaction call `` graft-vs.-host disease '' ( GVHD ) . GVHD donate immune cell transplant react body person receive cell . Tacrolimus give IV 2 week , give mouth pill least 3 month . Methotrexate give IV injection 3 4 dos first 11 day stem cell transplant . You also receive drug G-CSF ( Neupogen ) injection skin blood cell count reach certain high enough level . You need stay hospital 4 week . After leave hospital , continue outpatient hospital area , mean stay close enough able come back visit least 100 day transplant . You ask come back clinic 3 , 6 , 12 month transplant routine safety test . This include physical exam , bone marrow biopsy , routine blood draw . This investigational study . The way researcher make alloreactive NK cell use CLINIMACs device investigational . The CliniMACS device FDA approve . At time , use research . Up 18 patient take part study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients age &lt; /= 70 year one following : Acute myeloid leukemia past first remission , first subsequent relapse , second great remission primary induction failure ; Myelodysplastic syndrome intermediate high risk IPSS score ; CML progress accelerated phase blast crisis despite imatinib treatment 2 . Patients must HLA match ( HLA A , B , C , DR ) relate unrelated donor willing donate allogeneic peripheral blood progenitor cell transplantation . ( Recent large analysis National Marrow Donor Program indicate mismatch DQ locus adverse effect outcome . The current national standard care consider 4 locus identifying suitably `` match '' donor . ) 3 . Patients must haploidentical relative predict alloreactive base upon presence relevant KIR gene incompatibility recipient HLA C Bw antigens . 4 . Zubrod performance status &lt; /= 2 . 5 . Left ventricular ejection fraction &gt; /= 45 % . No uncontrolled arrhythmia uncontrolled symptomatic cardiac disease . 6 . No symptomatic pulmonary disease . forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) &gt; /= 50 % expect , correct hemoglobin . 7 . Serum creatinine &lt; /= 1.8mg % . 8 . Serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 200 IU/ml unless related patient malignancy . 9 . Bilirubin &lt; /= 1.5 mg/dl ( unless Gilbert 's syndrome ) .No evidence chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman consider liver biopsy . 10 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . 11 . No known allergy mouse proteins monoclonal antibody 1 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . The Protocol PI final arbiter eligibility . 2 . Pleural/pericardial effusion ascites estimate &gt; 1L . 3 . HIVpositive . 4 . Pregnancy : Positive Beta Human Chorionic Gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 5 . Known allergy mouse protein . 6 . Patient receive systemic chemotherapeutic drug ( include Mylotarg ) within 14 day prior trial enrollment unresolved grade &gt; 1 toxicity prior chemotherapy treatment . ( Hydroxyurea low dose arac less equal 20 mg/m2/d permit indicated control induction refractory disease , IT chemotherapy allow indicated maintenance treatment previously diagnose lumbar microdiscectomy ( LMD ) , remission prior enrollment study ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Leukemia</keyword>
	<keyword>NK Cells</keyword>
	<keyword>Natural Killer Cells</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>Busulfex</keyword>
	<keyword>MyleranÂ®</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Methotrexate</keyword>
</DOC>